MAXONA Pharmaceuticals today announced that the company has submitted an Investigational New Drug (IND) Application to the ...

A promising new treatment, however, may offer a safer path forward.

Study highlights novel epigenomic modulation in the central nervous system as a key mechanism for SRP-001's analgesic effects ...

The Subject Expert Committee (SEC) under the Central Drugs Standard Control Organisation (CDSCO) has asked Troikaa ...

The global analgesics market is on a robust upward trajectory, projected to achieve a revenue of USD 143.65 billion by 2034, ...

According to Statifacts, the global analgesics market size was evaluated at USD 88.89 billion in 2024 and is anticipated to hit around USD 143.42 billion by 2034, growing at a CAGR of 4.9% from 2025 ...

ART26.12, a Novel FABP5 Inhibitor, Demonstrates Sustained Analgesic Effects Without ToleranceSOLANA BEACH, Calif., July 09, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a ...

Xifyrm is indicated for use in adults for the management of moderate-to-severe pain, alone or in combination with non-NSAID analgesics.

The FDA has approved Xifyrm for use in adults for the management of moderate to severe pain, alone or in combination with non-NSAID analgesics.

Many medications, such as analgesics, antibiotics, and anesthetics, are available to help alleviate discomfort experienced with a toothache. Read more here.